Open AccessTo Assess Liraglutide’s Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System
Author(s) -
Jibin Yin,
Min Han,
Linhui Li,
Li Yang,
Zi'ang Liu,
Jing Yang,
Yunfeng Liu
Publication year - 2021
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s331833
Subject(s) - liraglutide , flash (photography) , continuous glucose monitoring , medicine , diabetes mellitus , type 2 diabetes mellitus , type 2 diabetes , intensive care medicine , endocrinology , type 1 diabetes , art , visual arts
Liraglutide, a type of glucagon-like peptide-1 receptor agonist, has significant anti-hyperglycaemic activity without increasing the incidence of hypoglycaemia. In addition, it can improve β-cell function and insulin resistance. The flash glucose monitoring system (FGMS) is a novel method to document consecutive and detailed interstitial glucose levels, further reflecting blood glucose levels. This study aimed to investigate the therapeutic effect of liraglutide on blood glucose management (glucose variability, hyperglycaemia, and the incidence of hypoglycaemia), β-cell function, and insulin resistance in patients with diabetes.